VEEV's Falcon and Vault AI deepen workflow automation across life sciences, while management expects AI revenues to remain immaterial in fiscal 2027.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The average of price targets set by Wall Street analysts indicates a potential upside of 41.9% in Veeva (VEEV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
VEEV lifts its full-year targets and highlights Falcon AI agents after a Q1 beat, with CRM migration wins and the Ostro deal shaping growth.
Veeva Systems beats Q1 earnings and revenue estimates, raises fiscal 2027 guidance, and expands AI offerings as adoption of its software platforms expands.
Veeva Systems Inc. (VEEV) Q1 2027 Earnings Call Transcript
Veeva is on the verge of a technical breakout. The beaten-down biopharma software firm's growth outlook is strong, and it's a cash cow with a stellar balance sheet.
Get a deeper insight into the potential performance of Veeva (VEEV) for the quarter ended April 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Veeva (VEEV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Veeva Systems (VEEV) closed the most recent trading day at $158.27, moving 4.06% from the previous trading session.
The latest trading day saw Veeva Systems (VEEV) settling at $164.96, representing a +1.01% change from its previous close.